Should I include a recording in the demo follow-up?

If you recorded it and they agreed, yes, plus timestamps for the two parts they cared about. A raw 40-minute link with no map is homework. Add the three bullets they'd need to brief a colleague. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

Is it okay to send this proposal follow-up on LinkedIn instead of email?

Yes if this CTO is actually active there and the thread isn't about long attachments. Keep the LinkedIn version even shorter. Don't paste the full email. One context line and one question is plenty. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

What should I never say in a Pharmaceuticals proposal follow-up?

Don't use consumer-startup slang. It's a credibility leak. Calling it 'AI-powered' with no description of the system. Don't send a 19-page deck that relitigates features they skipped. Those three mistakes show up constantly in Pharmaceuticals inboxes and they all read as "this was templated."

Can I use aggressive sales language in pharma outreach?

No. Unapproved claims, off-label hints, and fake urgency can create real problems. Be operational: timelines, review status, access, meeting logistics. Save clinical discussion for approved materials and the right role. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

How should a proposal follow-up to a Pharmaceuticals CTO change for after a demo?

Helpful and specific to what they clicked and asked. Don't invent clinical claims. Don't treat HCPs like a funnel. If you don't know the rules, your email is a liability. The CTO is guarding reliability, security, and engineering time, so the ask should stay at "a technical working session or a written teardown, not a 'vision call'." If you copy

Pharmaceuticals · CTO · After Demo

Proposal Follow-Up for Pharmaceuticals CTO: After Demo

The query is practical: what should a proposal follow-up email to a Pharmaceuticals CTO say for after a demo? Start with a direct answer, add one proof point about follow-up that ignores MLR, off-label risk, and the fact that 'just a quick claim' isn't quick, and close with ask who else needs to see it, or whether a narrower use

Last updated: 2026-09-02 · Reviewed by: Sales Email Template editors

We write templates the way we wrote emails on quota: short, specific, and easy to forward. When we cite research below, it is because the number changes how a buyer reads your note, not to pad the page.

Sources: HubSpot sales email benchmarks; Gong follow-up research

Why does this proposal follow-up work for a Pharmaceuticals CTO?

Diagnose the stall instead of asking if they 'had a chance to review.'
Speaks to follow-up that ignores MLR, off-label risk, and the fact that 'just a quick claim' isn't quick instead of a generic "value prop."
Fits how a CTO actually reads: 90 words is plenty if the substance is real. Don't pad.
Replay the two moments they leaned in, and the one concern they named.
Name the decision owner out loud.

When should I send this to a Pharmaceuticals CTO?

Wait until the review window you agreed on. If none was set, five business days. Same day with the recap. A value bump 3 days later if they went quiet. For this combo, treat "Same day, then 3 days if silent" as the default, then adjust around launch calendars and review boards set speed. you don't. If you're emailing a CTO, 90 words is plenty if the substance is real. Don't pad.

What this CTO actually cares about

A CTO in Pharmaceuticals is protecting reliability, security, and engineering time. They look for architecture, failure modes, and whether you'll create toil for their team. Fluff is a ranking signal that you don't know the work. The hook that earns a look is an incident class, a security gap, or a cost line they already hate. The ask should stay at this size: a technical working session or a written teardown, not a 'vision call'. Delete trigger: Calling it 'AI-powered' with no description of the system. If your note would embarrass them in a team channel, rewrite it.

How Pharmaceuticals changes the note

Pharmaceuticals buyers are commercial, medical, and ops leads who work under review boards and long timelines. Don't invent clinical claims. Don't treat HCPs like a funnel. If you don't know the rules, your email is a liability. A credible proof point in this vertical sounds like: cut review cycles on a leave-behind by catching claims issues before legal saw the tenth draft. Watch the language. Words that land here include MLR, label, access, HCP, congress, promotional review. Words that work: MLR, label, access, HCP, congress, promotional review. A thread that ignores follow-up that ignores MLR, off-label risk, and the fact that 'just a quick claim' isn't quick reads like every other vendor bump.

How should I customize this template before I send it?

Replace the pain line with an agency waiting on MLR while the sales team keeps asking 'is it approved yet'.
Keep the tone precise.
Set a decision date in the original proposal so this email has a hook.
Time it for Same day, then 3 days if silent. Same day with the recap. A value bump 3 days later if they went quiet.
Don't use consumer-startup slang. It's a credibility leak.

What mistakes should I avoid with this after demo note?

Asking 'any thoughts?' after a 12-page proposal invites silence.
Don't send a 19-page deck that relitigates features they skipped.
Don't use consumer-startup slang. It's a credibility leak.
Calling it 'AI-powered' with no description of the system.

How does this after demo scenario compare?

Dimension	For this template
Best send window	Same day, then 3 days if silent
Ideal length	90 words is plenty if the substance is real. Don't pad.
Primary ask	a technical working session or a written teardown, not a 'vision call'
Industry metric to cite	time through MLR, access, and compliant engagement rates
Tone	Precise. No slogans. It's fine to be a little dry.
Unlike after meeting	They have product context now. Speak to what they saw, not to a generic intro.
Unlike after proposal	Pricing may not be on paper yet. Don't jump to 'ready to sign.'

What should I copy and send?

Copy-ready template

Subject

Need a decision owner for [scope]

Body

Hi [First Name],

I sent the proposal last [day] and wanted to make the review easier.

In Pharmaceuticals, that usually shows up as follow-up that ignores MLR, off-label risk, and the fact that 'just a quick claim' isn't quick. If [competitor path] is still in play, I can send a one-page comparison on [criteria they named].

Replay the two moments they leaned in, and the one concern they named.

Want a 10-minute walkthrough for whoever else needs to see it?

Best,
[Your Name]
[Your Title]
[Your Company]

Questions people ask before they hit send

Not as an opening move. Ask what's blocking the decision first. If budget is the issue, trim scope or phase the work. Discounting before you know the objection trains them to wait you out. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

Related templates

Want a custom draft instead? Try the email generator.